You are here:
Aim of this study
The aim of the study is to ascertain the prevalence, risk factors, and progression of fertility limitations and possible reversibility for patients with chronic anemic diseases (primary diagnosis groups: sickle cell anemia, ß-thalassemia, Fanconi anemia, Diamond-Blackfan anemia, and others: sideroblastic anemia, congenital dysplastic anemia, and pyruvate kinase deficiency requiring transfusion).
(I) Fertility disorders are highly significant and can influence the quality of life of affected patients.
(II) Prevalence, risk factors and the progression of fertility disorders play a role in all chronic hematological diseases depending on the underlying disease and treatment.
(III) Hydroxyurea therapy, which is a critical contributor to prognosis in patients with sickle cell disease, is potentially gonadotoxic depending on duration and cumulative dose. However, it is not out of the question that the compromised fertility could recover given a significant post-therapeutic timespan.
(IV) Hematopoietic stem cell transplantation is used as a curative approach for severe chronic anemias. Its associated conditioning therapy is considered to be gonadotoxic even when reduced doses of chemotherapy and radiotherapy (mini-conditioning) are used prior to transplantation.-. However, it is not out of the question that the compromised fertility could recover given a significant post-therapeutic timespan.
(V) Patients with chronic anemias have a restricted reproductive window. However, fertility preserving measures designed to fulfill procreative goals are available.